Axogen, Inc. To the host Analyst & Investor Day on March 4th

Alachua, Florida and Tampa, Florida, February 25, 2025 (Globe Newswire) – Axogen, Inc. (Nasdaq: Axgn), a global market leader in the development and marketing of innovative surgical solutions for peripheral nerve injuries, will keep his analyst & investor on March 4, 2025 between 9 a.m. and 10 p.m. Eastern.

The responsible speakers include Chief Executive Officer – Michael Dale, Chief Financial Officer – Nir Naor, and other high -ranking members of the management team. During the event, the Axogen team will provide an overview of the business that offer strategic initiatives and growth plans and discuss financial results and goals.

A live webcast of the event will also be available and can be viewed under Axogen Virtual Analyst & Investor Day on the Axogen website of Axogen Relations. After the event, a repetition of the webcast is available for 90 days in the same place.

Axogen
Axogen (AXGN) is the leading company that focuses specifically on science, development and commercialization of technologies for regeneration and repair peripheral nerves. Axogen employees are passionate about helping patients with physical damage or transections to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health service providers. Peripheral nerves offer the paths for both motor and sensory signals in the entire body. Every day, people suffer traumatic injuries or are subject to surgical interventions that influence the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to correctly connect peripheral nerves can lead to the loss of muscle or organ function, loss of sensory feeling or to initiate pain.

The Axogen platform for repairing peripheral nerves has a comprehensive product portfolio that is used in two primary application categories: planned, non-trauma process and emerging trauma process. Planned procedures are generally characterized when a patient is looking for a relief of conditions caused by a nerve defect or surgical intervention. These procedures include that women after a mastectomy, nerve reconstruction after the surgical removal of painful neuromas, oral and maxillofacial interventions and nerve decompression who are looking for a sensation for women who have a breast reconstruction. Emergency procedures are generally characterized as procedures that result from injuries that are initially available in one. As a rule, these procedures are referred and completed immediately or within a few days after the initial injury.

Axogen's product portfolio includes Avance^® Nerve transplant, a biologically active off-the-the-helf-processed human nerve allotrobant for bridging peripheral nerves without the comorbidities associated with a second surgical body; Axoguard nerve connection^®a pig -submukosa -ecm coaptation aid for tension -free repairs of separated peripheral nerves; Axoguard nerve protection^®A pig -submucosa -ECM product that is used to wrap and protect the damaged peripheral nerves and to reinforce the nerve reconstruction and at the same time prevent soft tissue systems; Axoguard HA+ Nerve Protector ™, a base layer coated with a proprietary hyaluronate alginate gel, a porcin-submukosa ECM layer, a next generation technology that offers short and long-term protection for peripheral nerve injuries; AVIVE+ SWITCH TIBETRIX ™, a multi-Schayer amniotic membrane allotranslantat, which is used to protect and separate tissues in the surgical bed during the critical phase of the tissue repair; and Axoguard nerve cap^®A pig -submucosa -ECM product that is used to protect a peripheral end of the nerve and separate the nerve from the environment to reduce the development of the symptomatic or painful neuroma. The Axogen product portfolio is available in the USA, Canada, Germany, Great Britain, Spain, South Korea and several other countries.